# Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

> **NCT06406426** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

## Key facts

- **NCT ID:** NCT06406426
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406426, "Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06406426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*